WEST LAFAYETTE, Ind. (November 11, 2024) – Novilytic, an innovator in molecular recognition technology, is proud to announce the appointment of Johnston Erwin, Jonathan Edwardsen, and Alan Symons to its Board of Directors.
These appointments come as Novilytic embarks on a pivotal growth phase, with a sophisticated focus on scaling operations and enhancing strategic direction. The new board members’ diverse backgrounds will bolster the board’s ability to provide top-tier strategic oversight and guide Novilytic's following stages of growth and innovation.
Each new member brings specific strengths concerning Novilytic’s growth strategies and future investment and merger opportunities. Their backgrounds and strengths are highlighted below.
Johnston Erwin is the CEO of TRexBio and formerly was with Eli Lilly for over 35 years.
“Erwin's experience in the pharmaceutical industry, venture capital, and driving growth at smaller pharmaceutical startups is critical for our executive-level interactions in the future,” said Paul Dreier, CEO of Novilytic. He has held senior roles in large pharmaceutical companies and start-ups, bringing a unique perspective on scaling and structuring operations for growth in dynamic environments.”
Jonathan Edwardsen is the VP of Business Development at Veravas and has held roles with Agilent, LGC Standards, and Shimadzu.
“Edwardsen has an extensive background in mergers, acquisitions, and investments, which spans two of the largest companies in the analytical instrument space,” Dreier said. “His experience with his own startup and with big companies has made him a great advisor to me as we have grown Novilytic. His M&A and investment strategy expertise will be invaluable as we continue exploring strategic growth opportunities.”
Alan Symons has been AGS Capital's CEO for over 20 years and took two companies public on NASDQ while being CEO of two large insurance companies
“Symons brings a track record of building large companies and completing over 50 acquisitions and sales. When you add his wealth of knowledge, he will surely help us ensure great decisions,” Dreier said. His experience will support Novilytic’s next expansion phase, focusing on efficient capital allocation and sustainable growth.”
The new board members will play an essential role in Novilytic’s continued innovation and growth as the company leads the way in transforming the analysis and production of lifesaving protein-based medicines. We welcome them with open arms and cannot wait for them to help lead us to further success.
About Novilytic
Novilytic is a leader in molecular recognition technology. Their patented Proteometer product line is revolutionizing drug development and clone selection by eliminating sample preparation steps that save significant time and money. Their transformational technology fundamentally changes the production of antibody and protein-based medicines by providing near-real-time molecular structure analysis. This ultimately helps bring lifesaving treatments to the market faster. For more information, visit Novilytic.com.
###
Comments